



Health Technology Review	
Technology Ref.:	HTA21044
Technology Name:	HTA 130
Approvals by International Bodies:	CE certificate
Company name:	Horizon International Medical Supplies
Agent in UAE:	Dr. Mohamad kanbour
Email:	kanb@hims.ae; hims@hims.ae

Short Description of the Technology:	HA130 Hemoperfusion disposable cartridge demonstrated benefits on clearance of middle uremic toxins such as B2MG and PTH and protein bound toxins. HA130 combined with conventional haemodialysis showed benefits in the complications of haemodialysis such as the uremic pruritis, sleep disorders, refractory hypertension, and quality of life..The HA130 hemoperfusion cartridge to be used on any dialysis machine
---	--

Health Technology Assessment Team Recommendation:	Approve
Summary of Review:	
It is a disposable cartridge which is added to the dialyzer used for Uraemia, maintenance haemodialysis related complications & renal failure, the product is applicable to haemodialysis patients, its absorbers Middle to macro molecular toxins of uraemia. HA130 hemoperfusion therapy provides a new solution for ESRD complications.	
Advantages	Disadvantages
CE Marked Product	Lack of local cost effectiveness study
In dialysis patients, hemoperfusion is considered safe and effective when combined with conventional modalities.	Further studies are required to prove the efficiency of the HP cartridge on haemodialysis patients
Improve Quality of life for patients with Long - term haemodialysis; HP+HD joint treatment could prevent and improve long-term haemodialysis complications such as renal osteopathy, refractory skin pruritus, peripheral neuropathy, cardiovascular disease, refractory hypertension, nephro-encephalopathy, malnutrition etc. decrease morbidity of complications in long-term and short-term, prolong life span.	Risks of the technology are similar to the risks of the current practice; Complications of hemoperfusion.
Enhance the efficiency of the Dialysis process	limited peer reviewed clinical trials
Easy to use- Disposable	

We recommend an **approval of using this technology** with the following conditions:

1. Utilizing the Cartridge as per the manufacturer & treatments guidelines & standards for haemodialysis patients .
2. Additional SME feedback is required from Nephrologists.
3. Establishing a proper quality monitoring process and reporting of any adverse events or unwarranted consequences including safety issues of employees and Patient
4. Provision of regular updates and reports about the product to DOH upon request.
5. Any other documents or information requested regarding the product and cost to finalize the approval process.

Moreover, DOH has the right to stop the product at any stage if deemed necessary, initial conditions and any subsequent conditions must be satisfied before obtaining final approval. Failure to do so will reflect in provoking the approval.

Technology Image:





HA130 Use Criteria

Question	Answer	Comments
Which case?	haemodialysis patients; Long-term haemodialysis and hemofiltration in blood of end-stage renal disease (ESRD) patients	
Which doctors?	Nephrologists	
Which hospital?	Dialysis Centres- Specialized hospitals	
Inclusion criteria	chronic & ESRD haemodialysis patients	
	The hemoperfusion cartridge should be performed in association with dialyzer by connection in front of dialyzer, hemoperfusion treatment time is recommended as 120-150 mins.	
Exclusion criteria	Patients Allergic to dialysis equipment	As HA 130 could neither clear excess water in the uremic patient's body, nor regulate electrolyte and acid base balance, normally it was not advised to be employed alone.